MJFF awards $6m to Lario Therapeutics for Parkinson’s research
The neurological disease is estimated to affect more than ten million people globally
Read More
Tag: CaV2.3 calcium channel inhibition
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
